GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arqule Inc (NAS:ARQL) » Definitions » Gross Margin %

Arqule (Arqule) Gross Margin % : -3,896.63% (As of Sep. 2019)


View and export this data going back to 1996. Start your Free Trial

What is Arqule Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Arqule's Gross Profit for the three months ended in Sep. 2019 was $-8.11 Mil. Arqule's Revenue for the three months ended in Sep. 2019 was $0.21 Mil. Therefore, Arqule's Gross Margin % for the quarter that ended in Sep. 2019 was -3,896.63%.


The historical rank and industry rank for Arqule's Gross Margin % or its related term are showing as below:


ARQL's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 59.44
* Ranked among companies with meaningful Gross Margin % only.

Arqule had a gross margin of -3,896.63% for the quarter that ended in Sep. 2019 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Arqule was 0.00% per year.


Arqule Gross Margin % Historical Data

The historical data trend for Arqule's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arqule Gross Margin % Chart

Arqule Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -97.89 -38.46 -325.61 - -11.43

Arqule Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -45.83 -200.92 -453.75 -2,152.67 -3,896.63

Competitive Comparison of Arqule's Gross Margin %

For the Biotechnology subindustry, Arqule's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arqule's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arqule's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Arqule's Gross Margin % falls into.



Arqule Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Arqule's Gross Margin for the fiscal year that ended in Dec. 2018 is calculated as

Gross Margin % (A: Dec. 2018 )=Gross Profit (A: Dec. 2018 ) / Revenue (A: Dec. 2018 )
=-2.9 / 25.764
=(Revenue - Cost of Goods Sold) / Revenue
=(25.764 - 28.71) / 25.764
=-11.43 %

Arqule's Gross Margin for the quarter that ended in Sep. 2019 is calculated as


Gross Margin % (Q: Sep. 2019 )=Gross Profit (Q: Sep. 2019 ) / Revenue (Q: Sep. 2019 )
=-8.1 / 0.208
=(Revenue - Cost of Goods Sold) / Revenue
=(0.208 - 8.313) / 0.208
=-3,896.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Arqule  (NAS:ARQL) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Arqule had a gross margin of -3,896.63% for the quarter that ended in Sep. 2019 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Arqule Gross Margin % Related Terms

Thank you for viewing the detailed overview of Arqule's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Arqule (Arqule) Business Description

Traded in Other Exchanges
N/A
Address
One Wall Street, Burlington, MA, USA, 01803
Arqule Inc is a biopharmaceutical company, engaged in the research and development of therapeutics to treat cancers and rare diseases. The objective of the company is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of the patients. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Product portfolios of the group include Tivantinib, ARQ 087, ARQ 092, ARQ 761, and ARQ 751. Geographically, the firm operates through the region of United States.
Executives
Patrick J Zenner director C/O DENDRITE INTERNATIONAL INC., 1405/1425 ROUTE 206 SOUTH, BEDMINSTER NJ 07921
Marc Schegerin officer: CFO and Treasurer ARQULE INC, 1 WALL ST FL6, BURLINGTON MA 01803
Brian Schwartz officer: See Remarks C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Ran Nussbaum director C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Timothy C Barabe director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Susan L. Kelley director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Michael D Loberg director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Paolo Pucci director, officer: Chief Executive Officer C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Merck & Co., Inc. 10 percent owner 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Merck Sharp & Dohme Corp. 10 percent owner ONE MERCK DRIVE, WHITEHOUSE STATION NJ 08889
Robert J Weiskopf officer: Chief Financial Officer C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104

Arqule (Arqule) Headlines